(NASDAQ: ALT) Altimmune's forecast annual revenue growth rate of 2,271.26% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.71%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.57%.
Altimmune's revenue in 2025 is $15,000.On average, 1 Wall Street analysts forecast ALT's revenue for 2025 to be $17,651,450,600, with the lowest ALT revenue forecast at $17,651,450,600, and the highest ALT revenue forecast at $17,651,450,600. On average, 1 Wall Street analysts forecast ALT's revenue for 2026 to be $17,651,450,600, with the lowest ALT revenue forecast at $17,651,450,600, and the highest ALT revenue forecast at $17,651,450,600.
In 2027, ALT is forecast to generate $7,309,906,980 in revenue, with the lowest revenue forecast at $3,265,518,361 and the highest revenue forecast at $11,354,295,598.